Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 2Myeloid 2Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Leukemia 41Leukemia, Myeloid, Chronic-Phase 35Blast Crisis 17Philadelphia Chromosome 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Accelerated Phase 10Leukemia, Myeloid 9Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myeloid, Acute 7Polycythemia Vera 6Myeloproliferative Disorders 6Hypereosinophilic Syndrome 5Hematologic Neoplasms 5Hematologic Diseases 5Bone Marrow Diseases 5Multiple Myeloma 4Gastrointestinal Stromal Tumors 4Thrombocythemia, Essential 3Myelodysplastic Syndromes 3Mastocytosis 3Leukemia, Lymphocytic, Chronic, B-Cell 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm, Residual 2Mastocytosis, Systemic 2

Interventions

fludarabine phosphate 34Cyclophosphamide 31Peripheral Blood Stem Cell Transplantation 27Mycophenolic Acid 25Cyclosporine 23Antilymphocyte Serum 23Busulfan 20Tacrolimus 17Radiotherapy 17Filgrastim 17Whole-Body Irradiation 15Methotrexate 15Methylprednisolone 14Melphalan 13Cord Blood Stem Cell Transplantation 12venetoclax 9Cytarabine 8Azacitidine 8fludarabine 5Etoposide 5sargramostim 4Therapeutics 4Sirolimus 4Decitabine 4Clofarabine 4Alemtuzumab 4thymoglobulin 3nilotinib 3merphos 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Imatinib Mesylate × Myeloid × Clear all
NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Novartis

Phase 1 Completed
326 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Fred Hutchinson Cancer Center

Phase 2 Completed
28 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡